Self-Nanoemulsion Loaded with a Combination of Isotretinoin, an Anti-Acne Drug, and Quercetin: Preparation, Optimization, and In Vivo Assessment

Khaled M. Hosny 1,2,*, Khalid S. Al Nahyah 1 and Nabil A. Alhakamy 1,2

1 Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Kabdullahalnahyah@stu.kau.edu.sa (K.S.A.N.); nalhakamy@kau.edu.sa (N.A.A.)
2 Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia
* Correspondence: kmhomar@kau.edu.sa; Tel.: +966-5-9272-2634

Abstract: Acne vulgaris is a common skin disease that affects everybody at least once in their lives. The treatment is challenging because the stratum corneum contains rigid corneocytes surrounded by intercellular lamellae that are difficult to bypass. In the present study, we intended to formulate an effective nanoemulsion that could deliver isotretinoin (ITT) with enhanced solubility, permeability, and bioavailability across the skin. ITT can have a serious hepatotoxic effect if given too frequently or erratically. Therefore, to overcome the aforesaid limitation, quercetin (QRS), a hepatoprotective agent, was incorporated into the formulation. Initially, the ITT solubility was determined in various surfactants and cosurfactants to select the essential ingredients to be used in the formulation and to optimize a nanoemulsion that could enhance the solubility and permeability of ITT and its antimicrobial activity against Staphylococcus aureus, which is the main microorganism responsible for acne vulgaris. The mixture design was applied to study the interactions and optimize the independent variables that could match the prerequisites of selected dependent responses. A formulation containing 0.25 g of rosehip oil, 0.45 g of surfactant (Lauroglycol-90), and 0.3 g of cosurfactant (propylene glycol) was chosen as an optimized desirable formulation. The optimized batch was loaded with QRS and evaluated for in vitro and ex vivo permeation. The in vivo hepatotoxicity was assessed through topical administration. Permeability studies confirmed the enhanced permeation percentage of ITT (52.11 ± 2.85%) and QRS (25.44 ± 3.18%) of the optimized formulation, with an enhanced steady-state flux (Jst). The in vivo studies conducted on experimental animals demonstrated superior hepatoprotective activity of the prepared optimized formulation compared with other formulations of drugs and commercially marketed products. We anticipate that this optimized ITT formulation, followed up with good clinical evaluations, can be a breakthrough in the safe treatment of acne vulgaris.

Keywords: isotretinoin; acne; nanoemulsion; hepatoprotective; Box–Behnken Design

1. Introduction

Acne is the common skin disease for which most patients attempt to get a dermatologic cure [1,2]. Recently, dermatological and cosmetic efforts have begun to concentrate on the microbiome of the human skin. Staphylococcus aureus adapts to evolving microenvironments of the skin and may become an opportunistic pathogen causing acne or atopic dermatitis [3]. S. aureus is a gram-positive, anaerobic organism that usually causes superficial sebaceous unit infections [4]. However, the precise contribution of S. aureus to acne is not entirely clear [5]. In chronic inflammatory skin diseases, the microbe can amplify symptoms. The first step in patients is to elucidate their potential role in skin diseases compared with controls. This could lead to new options for more focused antimicrobial therapy [6]. Acne treatment goals include scar reduction and the resolution of lesions. Acne grading depending on the form and severity of the lesions will help guide care [7].
The most commonly used drug for acne is isotretinoin (ITT), which is a synthetic form of vitamin A. It is very effective for mild nodular and extreme papulopustular acne [8]. ITT effectively addresses all aspects of acne pathogenesis; it not only decreases keratinocyte proliferation and thus reduces follicular hyperkeratinization, but also relieves sebaceous gland inflammation and slows sebum development [9]. The pharmacological profile of ITT suggests that it acts primarily by reducing the size of sebaceous glands and the production of sebum, and as a result, it alters the skin surface lipid composition. Bacterial skin microflora are reduced, probably as a result of altered sebaceous factors. ITT 1 to 2 mg/kg/day for 3 to 4 months produces 60% to 95% clearance of inflammatory lesions in patients with severe, recalcitrant nodulocystic acne, and there is evidence of continued healing and prolonged remissions in many patients after treatment withdrawal. In 2016, the American Academy of Dermatology approved ITT for the treatment of moderate acne that either produces physical scarring or is treatment resistant [10,11]. The low oral bioavailability of ITT in animals can result from the biodegradation of the drug in the gastrointestinal (GI) lumen and/or drug metabolism during absorption (in the GI mucosa) and the first passage through the liver. ITT can have a significant effect on the population of resident microbes by eliminating their supply of critical nutrients and stabilizing immune hypersensitivity [12]. Over the decades, no other drugs or treatments have been as significantly effective as ITT. Nonetheless, despite these fascinating features, the drug’s extremely low solubility and permissibility can limit its incorporation into a suitable vehicle and lead to poor patient compliance. ITT can cause a dose-related elevation of blood triglyceride and cholesterol levels; it increases the level of triglyceride in 50% of patients and cholesterol in 30%. Ahmadvand et al. showed that before and after ITT therapy, both triglyceride and cholesterol levels had significant statistical differences [13]. ITT can interact with certain essential groups at the active sites of important proteins or enzymes in the lipid metabolism, such as hydroxymethylglutaryl (HMG), a key regulatory enzyme that plays an important role in the metabolism of cholesterol. ITT can also cause an elevation in the liver transaminases in a dose-dependent manner during treatment [13]. Consequently, it is prudent to enhance the solubility of ITT and minimize its adverse effects by using an appropriate carrier.

Several plant-derived natural products, characterized by a huge structural diversity, including phenolic compounds, are cited as antimicrobial agents and resistance-modifying agents [14]. One such compound is quercetin, which comprises a variety of phenolic hydroxyl groupings with significant anti-inflammatory properties and antioxidant effects [15]. Quercetin was reported to have strong, long-lasting anti-inflammatory effects [16]. Its anti-inflammatory potential can be expressed on different cell types in animal and human models (Chirumbolo, 2010). The QRS mainly remained in the layers of the human stratum corneum. The properties of quercetin have potential benefits for overall health and disease resistance, including anticarcinogenic [17], anti-inflammatory, antiviral, antioxidant, and psychostimulant benefits. The drug can also inhibit lipid peroxidation, platelet aggregation, and capillary permeability and can stimulate mitochondrial biogenesis [18–20]. Quercetin’s antioxidant features can assist in the care and appearance of the skin [21]. The key downside of quercetin applications via nanodelivery techniques is stability and effectiveness of penetration. We conclude that quercetin can be used to make different cosmeceutical nanosized products with improved stability and sustained beautifying effects and no harmful side effects [22].

The self-nanoemulsifying drug delivery system (SNEDDS) is a nanocarrier that forms spontaneously from the mixture of an oil, surfactant, cosurfactant, and active drug compound in a homogenous, fine, oil-in-water, nanoemulsion liquid form [23]. In recent years, much attention has been paid to SNEDDS. The systems have had reasonable success in improving the bioavailability of poorly soluble drugs, especially topical drugs. Nanoemulsions have also been used for the decontamination of radionuclei and photodynamic therapies. Consequently, nanoemulsions have many applications in the field of dermatology [24]. SNEDDS have a broad interfacial surface area because
of their small globule size, and this enhances drug absorption and bioavailability by improving drug release and membrane permeation and reducing presystem metabolism and efflux pumping [25]. Many therapeutic agents, such as antioxidants, nonsteroidal anti-inflammatory drugs, and lipids were successfully formulated using nanoemulsions as novel carriers for topical application. Consequently, nanoemulsions have many applications in the field of dermatology [26].

Numerous scientific studies were done over the years on the application of essential oils in nanoemulsions. An essential oil can be a suitable natural alternative to a synthetic skin penetration enhancer due to its low cost and its ability to improve penetration [27]. Rosehip oil extracted from *Melaleuca alternifolia* has a unique application in the treatment of acne. Owing to its improved bacteriostatic activity and ability to minimize lesion formation, rosehip oil has been used to treat seborrheic dermatitis and acne vulgaris. There are several drawbacks related to its topical application, such as the potential production of irritant or allergic contact dermatitis, decreased penetration in the affected area, and potential alteration of cutaneous flora [28]. It was allegedly used in Persian medicine to relieve inflammation, cure infectious diseases, and heal wounds [29]. In the treatment of acne, rose oil was used; it is a multifunctional component that may be integrated into cosmetic products [30,31].

In contrast to several conventional methods, the topical route offers an alternative form of drug delivery and attracts innovative research, particularly in the treatment of several skin diseases. The potential nanotechnology strategy circumvented the physicochemical and pharmacokinetic constraints of QRS and ITT. Nonetheless, very few studies have discussed the crucial findings of the in vivo results of this advanced method. Therefore, this study used a mixture design to create an optimized formulation of quercetin and ITT to improve their bioavailability and antimicrobial activity and to reduce ITT toxicity.

2. Materials and Methods

2.1. Materials

ITT was purchased from Wuhan Senwayer Century Chemical Co., Ltd. (Wuhan, China). Rosehip oil was obtained from Hayward, CA, USA. Quercetin was procured from Water Import and Export Co., Ltd. (Exiamen, China). Lauroglycol-90 was generously gifted by Gattefosse (Lyon, France). Propylene glycol, Tween, Span, and Cremophor were purchased from Sigma (St. Louis, MO, USA). All other reagents and chemicals used were of analytical grades.

2.2. Methods

2.2.1. Determination of ITT Solubility

The solubility of ITT in rosehip oil and different surfactants and cosurfactants was determined. An excess amount of ITT was dissolved in approximately 3 mL of each vehicle individually. The mixture was then shaken on a water bath (Model-1031, GFL Corporation, Lüneburg, Germany) for 72 h, and the temperature was maintained at 37 ± 0.5 °C. Once equilibrium was attained, the resulting mixture was centrifuged (3K30 Centrifuge, Sigma Aldrich, Gillingham, Dorset, UK) at 8 °C for 30 min at 15,000 rpm. The formed supernatant was diluted with a suitable quantity of methanol and analyzed quantitatively for the ITT concentration using a UV-Visible spectrophotometer at 362 nm. The experiment was repeated three times, and the values were noted as the mean ± the standard deviation.

2.2.2. Pre-Formulation Studies

Several formulations were designed with selected proportions of rosehip oil, Lauroglycol-90 surfactant, and propylene glycol cosurfactant and measured for particle size using the Zetatrac particle size analyzer (Microtrac, Inc., Montgomeryville, PA, USA) in accordance with the study design. Initially, 10 formulations were prepared (Table 1) using different concentrations of ITT (20 to 60 mg) and different proportions of rosehip oil, Lauroglycol-90, and propylene glycol. The amount of QRS in each formula was equal to ITT. QRS at
lower doses can be very useful in maintaining human health; at higher doses, QRS has proapoptotic actions on healthy cells but can kill tumor cells.

Table 1. Preliminary formulation prepared to study the emulsification of isotretinoin (ITT) and quercetin (QRS).

| Formula | Formulation                                      |
|---------|--------------------------------------------------|
| 1       | Rosehip oil (0.2 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.2 g) + 20 mg ITT + 20 mg QRS |
| 2       | Rosehip oil (0.2 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.2 g) + 40 mg ITT + 40 mg QRS |
| 3       | Rosehip oil (0.2 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.2 g) + 60 mg ITT + 60 mg QRS |
| 4       | Rosehip oil (0.3 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.1 g) + 20 mg ITT + 20 mg QRS |
| 5       | Rosehip oil (0.3 g) + Lauroglycol-90 (0.4 g) + Propylene glycol (0.3 g) + 20 mg ITT + 20 mg QRS |
| 6       | Rosehip oil (0.1 g) + Lauroglycol-90 (0.7 g) + Propylene glycol (0.2 g) + 20 mg ITT + 20 mg QRS |
| 7       | Rosehip oil (0.1 g) + Lauroglycol-90 (0.5 g) + Propylene glycol (0.4 g) + 20 mg ITT + 20 mg QRS |
| 8       | Rosehip oil (0.2 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.2 g) + 20 mg ITT + 20 mg QRS |
| 9       | Rosehip oil (0.3 g) + Lauroglycol-90 (0.6 g) + Propylene glycol (0.1 g) + 20 mg ITT + 20 mg QRS |
| 10      | Rosehip oil (0.1 g) + Lauroglycol-90 (0.5 g) + Propylene glycol (0.4 g) + 20 mg ITT + 20 mg QRS |

2.2.3. Mixture Design for the Development of ITT-QRS-Loaded SNEDDS

Statistical optimization of the response surface methodology (RSM) has proven to be a proficient tool in optimizing the various parameters in a multifarious process to obtain the desired responses; thus, it has been applied to formulate ITT-QRS SNEDDS. Among several models, the I-optimal point-exchange mixture design was selected to study the interaction of independent variables. Three factors were selected, namely, the percentage of rosehip oil (X1), surfactant (Lauroglycol-90) (X2), and cosurfactant (propylene glycol) (X3) (Table 2). Data from the previous pre-formulation studies were used to choose the levels of independent variables. All these components were used selectively in several ratios, with a total concentration equal to 100%. A total of 16 runs were projected, and the variables are summarized in Table 3. All these variables were selected with regard for the fact that the developed formulation was specially meant for topical application. The globule size (Y1), steady-state inflow (Y2), and inhibition zone (Y3) play vital roles in the delivery of active ingredients to the site of action. The correlations between the selected variables and responses were further analyzed by applying the regression equation using Statgraphics Centurion XV software version 15.2.05 (StatPoint Technologies, Warrenton, VA, USA). The SNEDDS formulation was optimized for the minimum globule size, highest Jss, and maximum inhibition zone.

Table 2. Experimental mixture design (component levels and selected responses).

| Component              | Level | Response Constraints |
|------------------------|-------|----------------------|
| Rosehip oil (%), (X1)  | Low   | Mean globule size (Y1) Minimum |
|                        | High  |                      |
| Lauroglycol-90 (%), (X2)| Low   | Steady-state inflow (Jss) (Y2) Maximum |
|                        | High  |                      |
| Propylene glycol (%), (X3)| Low | Inhibition zone (Y3) Maximum |
|                        | High  |                      |

2.2.4. Preparation of ITT-QRS Nanoemulsion

Various formulations of ITT-QRS nanoemulsions were prepared, as portrayed in the design mixture (Figure 1). First, ITT and QRS were added to the rosehip oil; subsequently, a mixture of Lauroglycol-90 and propylene glycol was added. The formed mixture was further sonicated using Ultrasonic Processors (VCX 750, Sonics & Materials, Inc., Newtown, CT, USA) to aid in the dissolution of ITT within the formed mixture. The formed mixture was homogenized for 3 min using a 1.3-mm stainless steel probe. At this stage, the formulation could be further loaded with quercetin as required. Finally, the formed dispersion (self-nanoemulsifying system) was added to distilled water drop by drop, and
the final nanoemulsions were formed spontaneously during mixing at room temperature (Figure 1).

Table 3. Mixture design for the development of ITT-QRS-loaded self-nanoemulsifying drug delivery system (SNEDDS).

| Run | (X1): Oil (Rosehip Oil) | (X2): Surfactant (Lauroglycol-90) | (X3): Cosurfactant (Propylene Glycol) |
|-----|-------------------|-------------------------------|---------------------------------|
| 1   | 0.3               | 0.5                           | 0.2                             |
| 2   | 0.2               | 0.5                           | 0.3                             |
| 3   | 0.3               | 0.533333                      | 0.166667                        |
| 4   | 0.2               | 0.6                           | 0.2                             |
| 5   | 0.2               | 0.6                           | 0.2                             |
| 6   | 0.233333          | 0.533333                      | 0.233333                        |
| 7   | 0.166667          | 0.566667                      | 0.266667                        |
| 8   | 0.2               | 0.5                           | 0.3                             |
| 9   | 0.3               | 0.6                           | 0.1                             |
| 10  | 0.1               | 0.6                           | 0.3                             |
| 11  | 0.2               | 0.5                           | 0.3                             |
| 12  | 0.2               | 0.6                           | 0.2                             |
| 13  | 0.266667          | 0.466667                      | 0.266667                        |
| 14  | 0.1               | 0.6                           | 0.3                             |
| 15  | 0.3               | 0.466667                      | 0.233333                        |
| 16  | 0.3               | 0.4                           | 0.3                             |

Figure 1. Preparation of ITT nanoemulsion.

2.2.5. Characterization of ITT-QRS Nanoemulsion

Prepared ITT-QRS SNEDDS were characterized by various parameters to study the effect of selected variables.

Measurement of Globule Size

For each formulation, 100 μL of the formulation was diluted with 900 μL of distilled water to form an aliquot of 1 mL, and the globule size of the prepared sample was determined at 25 °C using a dynamic light-scattering technique (Zetatrac, Microtrac, Montgomeryville, PA, USA) [30].

Ex Vivo Permeation Studies to Evaluate the Jss of ITT from Each Formula

The ex vivo permeation test was done with a simple, low-head dissolution testing instrument (PT-DT70, Pharma Test Apparatebau AG, Hainburg, Germany). The receptor compartment was filled with 450 mL of phosphate buffer with continuous stirring at 50 rpm. The temperature of the buffer solution was maintained at 37 ± 0.5 °C. The required area of skin (2 cm × 2 cm) was collected from a Wistar rat’s abdominal segment (hairless). Animals
were collected from the Animal House at the Beni-Suef clinical laboratory center after obtaining approval from the ethical committee (Approval No. 22-09-20). Obtained skin was soaked in a phosphate buffer at a pH of 7.2 for 1 day before the study began. Afterward, the skin segment was placed between the donor and receptor compartments so that the dermal side would be in close contact with the receptor side. At specific intervals, aliquots of 3-mL samples were withdrawn, and the value of the Jss for each formula was analyzed using a UV-Visible spectrophotometer (Jenway 6705, Cole-Parmer, Stone, Staffordshire, UK). The QRS and ITT were quantitatively measured at 269 nm and 299 nm, respectively.

**Inhibition Zone against *Staphylococcus aureus***

An antibacterial activity test assessing the inhibition zones produced by the test formulations was performed by plating 20 mL of agar (cooled) plus an *S. aureus* inoculum into a petri dish. When set, the agar was punched with a sterile cork-borer 12 mm in diameter, and 100 µL of each formulation was added to the bores. After incubation at 37 °C for 18 h, the inhibition zones were measured with a ruler (*n* = 3). Sterile water was used as a negative control.

**2.2.6. Optimization of ISN Formulations***

The obtained results from the experimental runs were further analyzed using the ANOVA (analysis of variance) with a multiple-response optimization. The optimized formulation was selected based on the constraints of the selected responses.

**2.2.7. Preparation and Evaluation of the Optimum Formula According to the Mixture Design***

After the optimization of the experimental runs, an optimized formulation was prepared according to the concentrations proposed by the software and evaluated for globule size, ex vivo permeation, and inhibition zone against *S. aureus*. In addition, the following tests were done on the optimized formula.

**2.2.8. In Vitro Release Studies***

In vitro drug release studies were performed to calculate the amount of ITT and QRS released in the optimized formulation. A low-head dissolution testing instrument, PT-DT70, with a dialysis cellulose membrane diffusion area of 4 cm² (Cutoff 14,000 Da pore size; Sigma-Aldrich, St Louis, MO, USA) was utilized. First, the dialysis membrane was soaked in a phosphate buffer (pH 7.4) for 15 min at 25 ± 0.5 °C. The receptor compartment was filled with the phosphate buffer, and the paddle was placed in the medium with continuous rotations (75 rpm). The temperature was maintained at 37 ± 0.5 °C throughout the experiment. Samples were withdrawn at various time intervals (1, 2, 3, 4, 6, 8, and 12 h), and the ITT and QRS concentrations were analyzed at 269 and 299 nm, respectively.

**2.2.9. Animal Studies***

Forty-two male adult mice weighing 20.5 ± 1.5 g were selected and adapted for 7 days before the study. The animals were divided into seven groups consisting of six animals in each group. All groups and the tested formulations are shown in Figure 2. At the end of the study period, the hepatic function parameters were estimated by measuring the AST, ALT, malondialdehyde (MDA), and glutathione peroxidase (GSH-Px).
The enhanced solubility of ITT has been recorded with propylene glycol (20.1 ± 3.11 µg/mL). Propylene glycol is known for its great miscibility in polar and nonpolar solvents, as well as its ability to increase absorption and the degree of permeability [34]. Thus, it serves as a...
carrier (cosurfactant) in formulating nanoemulsions. Propylene glycol can penetrate and interact with the stratum corneum to modify the permeability of several therapeutic agents. Several studies have confirmed the enhanced solubility and permeability of propylene glycol as a vehicle [35]. Rosehip oil also solubilizes ITT because it is a hydrophobic “drug” to a reasonable extent. Based on these results, the surfactant Lauroglycol-90, cosurfactant propylene glycol, and essential oil rosehip oil were selected to formulate the SNEDDS.

3.2. Pre-Formulation Studies

The particle sizes of all the prepared formulations were evaluated. First, the concentration of ITT to be used for further formulations was optimized. Formulation 1, having higher concentrations of ITT (20, 40, and 60 mg), resulted in a particle size of 114.11 ± 13.28 nm, 186.22 ± 13.62 nm, and 350.44 ± 21.32 nm (Table 4). Therefore, a concentration of 20 mg of ITT was selected in the research. The identical phenomenon was observed with formulations 2 and 3. Among the selected doses of ITT, a 20-mg daily dose seems to be an effective and safe treatment option for patients with moderate to severe acne, with a lower incidence of side effects. To the best of our knowledge, there is no reported use in the literature of a fixed 20-mg daily ITT dose until a cumulative dose of 0.5–1 mg/kg has been reached. This was supported by the work done by Abbas Rasi et al. As a result, a concentration of 20 mg of ITT was used consistently to prepare the remaining formulations. And in each tested formula amount of QRS was equal to that of ITT [1:1 ratio of ITT:QRS]. (Table 4) [36].

Table 4. Particle size and ITT content of different formulations prepared during pre-formulation step. Data are presented as mean ± SD (n = 3).

| Formula | Amount of ITT (mg) | Particle Size ± SD (nm) |
|---------|-------------------|------------------------|
| 1       | 20                | 114.11 ± 13.28         |
| 2       | 40                | 286.22 ± 15.62         |
| 3       | 60                | 350.44 ± 21.32         |
| 4       | 20                | 311.21 ± 12.33         |
| 5       | 20                | 297.22 ± 11.11         |
| 6       | 20                | 91.12 ± 6.75           |
| 7       | 20                | 81.33 ± 2.76           |
| 8       | 20                | 130.21 ± 12.3          |
| 9       | 20                | 350.55 ± 16.1          |
| 10      | 20                | 100.34 ± 7.80          |

3.3. Optimization of ITT-Loaded SNEDDS

The mixture design was used to analyze the effect of selected independent variables on the minimum globule size (Y1), maximum Jss (Y2), and larger inhibition zone (Y3). The design projected 16 runs, and the observed responses are given in Table 5. The globule size in all the trial batches was found to be 130 to 390 nm. The Jss and inhibition zone were estimated to be 95 to 270 µg/cm²/h and 3 to 27 mm, respectively (Table 5). All obtained results were evaluated for individual responses. The effect of selected variables was further analyzed statistically using the ANOVA.

Based on the fit summary of the responses (adjusted and predicted R2 values) and the sequential sum of squares (Type I), different models were selected (Table 6). No models were misidentified with the highest-order polynomial equations [37]. The accuracy of the model was further evaluated using the normal probability of studentized residuals. Externally studentized results were scattered around the straight line with a slight deviation. The ANOVA was further used to quantitatively analyze the relationship between the selected independent variables and the responses.
Table 5. Projected trial formulations and their observed responses according to the mixture design.

| Run | Globule Size * (nm) | Jss * (µg/cm²/h) | Inhibition Zone * (mm) |
|-----|---------------------|------------------|------------------------|
| 1   | 370 ± 13            | 115 ± 9          | 25 ± 4                 |
| 2   | 220 ± 11            | 240 ± 13         | 9 ± 2                  |
| 3   | 355 ± 14            | 95 ± 7           | 26 ± 6                 |
| 4   | 200 ± 10            | 130 ± 9          | 11 ± 2                 |
| 5   | 199 ± 10            | 128 ± 6          | 12 ± 4                 |
| 6   | 265 ± 13            | 135 ± 11         | 15 ± 2                 |
| 7   | 167 ± 14            | 205 ± 14         | 6 ± 2                  |
| 8   | 218 ± 12            | 238 ± 12         | 8 ± 3                  |
| 9   | 340 ± 16            | 107 ± 10         | 27 ± 5                 |
| 10  | 130 ± 9             | 270 ± 17         | 3 ± 1                  |
| 11  | 217 ± 13            | 235 ± 23         | 9 ± 4                  |
| 12  | 203 ± 12            | 127 ± 11         | 11 ± 2                 |
| 13  | 300 ± 14            | 177 ± 16         | 19 ± 4                 |
| 14  | 132 ± 17            | 268 ± 12         | 3 ± 1                  |
| 15  | 381 ± 12            | 140 ± 15         | 24 ± 5                 |
| 16  | 390 ± 18            | 220 ± 18         | 23 ± 2                 |

* Average ± SD (n = 3).

Table 6. Fit Summary for responses.

| Source       | Globule Size | Jss | Inhibition Zone |
|--------------|--------------|-----|-----------------|
|              | Adjusted R²  | Predicted R² | Adjusted R² | Predicted R² | Adjusted R² | Predicted R² |
| Linear       | 0.9455       | 0.9217     | 0.8463       | 0.7051       | 0.9420       | 0.9160       |
| Quadratic    | 0.9933       | 0.9896     | 0.9943       | 0.9887       | 0.9948       | 0.9937       |
| Special Cubic| 0.9926       | 0.9783     | 0.9950       | 0.9695       | 0.9950       | 0.9881       |
| Cubic        | 0.9996       | 0.9989     |               |              |              |              |

Response I: The selected model was statistically significant, $F = 32, p < 0.01%$. Polynomial equations were generated using multiple regression analysis. Both the $p$-values and polynomial equations were used to estimate the true effect of the variables. $p$-values that were less than 0.0001 were considered statistically significant. Values greater than 0.1000 indicated that the model terms were not significant. If there were many insignificant model terms (not counting those required to support the hierarchy), model reduction could have been required. The lack-of-fit $F$-value (0.52) was nonsignificant, with only a 13.5% chance that a lack-of-fit $F$-value this large could occur due to noise.

Adequate precision measured the signal-to-noise ratio. In general, a ratio greater than 4 is desirable. The obtained ratio (194.91) indicated an adequate signal to navigate the design space [38]. ANOVA results revealed the significant statistical relationship between the components and responses at a 95% confidence level.

Based on the ANOVA results, Response I was affected significantly by the synergistic effect of a linear mixture ($p < 0.0001$) between rosehip oil and other factors, but the predominant effect was for rosehip oil [39,40] with the highest magnitude (Table 7). The polynomial equation can be further applied to predict the response from any given concentration of independent variables. The equation was generated at the point where lower concentrations of independent factors could contribute to the formation of globules with a minimum size.

Final Equations with Coded Factors

Globule size ($Y1$) = +157.19 X₁ − 1011.05 X₂ + 1161.66 X₃ + 3067.47 X₁X₂ − 1077.94 X₁X₃ + 222.78 X₂X₃ − 2252.11 X₁X₂X₃

Several studies have reported that increased oil levels can increase the globule size. This can be due to the coalescence of oil droplets and the added concentrations of surfactants or cosurfactants. Conversely, increasing the proportion of Lauroglycol-90 can reduce the globule size. RSM has been applied to analyze the effects of these selected factors.
Contour plots and three-dimensional graphs for Response I are shown in Figure 4. The mixture’s three components are depicted in the corners of the triangle, and the center portion illustrates the mixture.

Table 7. ANOVA results in three responses.

| Term         | Responses |       |       |       |
|--------------|-----------|-------|-------|-------|
|              | Globule Size |       | Jss  | Inhibition Zone |
|              | F-Value | p-Value | F-Value | p-Value | F-Value | p-Value |
| Model        | 4645.30 | <0.0001 | 928.75 | <0.0001 | 574.28 | <0.0001 |
| Linear Mixture | 19,919.44 | <0.0001 | 3223.03 | <0.0001 | 1368.24 | <0.0001 |
| AB           | 74.69 | 0.0001 | 18.73 | 0.0034 | 74.79 | <0.0001 |
| AC           | 30.07 | 0.0015 | 42.96 | 0.0003 | 55.22 | <0.0001 |
| BC           | 1.30 | 0.2975 | 29.73 | 0.0010 | 0.1197 | 0.7365 |
| ABC          | 30.87 | 0.0014 | 0.0041 | 0.9510 | — | — |
| AB (A to B)  | 154.29 | <0.0001 | 6.63 | 0.0367 | — | — |
| AC (A to C)  | 165.73 | <0.0001 | 20.28 | 0.0028 | — | — |
| BC (B to C)  | 13.88 | 0.0098 | 928.75 | <0.0001 | — | — |

Response II: The model F-value (11.08, \( p < 0.01 \)) and lack-of-fit F-value (4.36) for Response II confirmed that the selected model was significant, and the lack of fit was not significant, relative to the pure error. Adequate precision (84.54) indicated an adequate signal to navigate the design space. Based on the ANOVA results (Table 7) for the cubic model, \( X_1, X_3, X_2X_3, X_1X_2X_3 \), and \( X_2X_3 \) factors affected Response II antagonistically at a \( p \)-value of less than 0.0001, and all remaining factors showed a synergistic effect (Table 4). The generated polynomial equation shows that all these selected variables significantly affected the Jss. The mixture design contour plots and three-dimensional plots were similar to those for Response I. As discussed in the previous sections, higher concentrations of surfactants and rosehip oil account for an elevated and decreased Jss, respectively.

Final Equations with Coded Factors

\[
J_{ss} (Y_2) = +497.49 \times X_1 + 408.09 \times X_2 + 915.05 \times X_3 - 1382.62 \times X_1X_2 - 1944.53 \times X_1X_3 - 1569.70 \times X_2X_3
\]

Response III: The adequate precision for the linear model of Response III was 36.366, which is greater than 4, suggesting that the model could navigate the design space. The ANOVA results confirmed the significant effect of the linear mixture (\( p < 0.0001 \)). The three selected components are depicted in the corners of the triangle, and the three-dimensional contour plots were drawn to study the interaction effects. The fitted linear special regression equation was generated as shown below.

Final Equations with Coded Factors

\[
\text{Inhibition zone} = 78.95 \times X_1 + 8.39 \times X_2 - 4.30 \times X_3 - 66.65 \times X_1X_2 - 57.07 \times X_1X_3 + 3.12 \times X_2X_3
\]

The above results showed a higher significant effect of the rosehip oil concentration compared with the other variables. This was due to the antimicrobial properties of the rosehip oil [41,42].

The process was optimized by setting the goals for every response and simultaneously applying the global desirability function (D). Based on these criteria, the desirability plot was generated with a D value of 1 (Figure 5). In conclusion, a formulation with 0.25 g of the oil mixture, 0.45 g of the surfactant (Lauroglycol-90), and 0.3 g of the cosurfactant (propylene glycol) fulfilled the optimum formulation requirements. Using these variables can result in a formulation with a globule size of 249 nm, Jss of 222.05 \( \mu g/cm^2/h \), and inhibition zone of 15 mm.
Globule size ($Y_1$) = $+157.19 X_1 - 1011.05 X_2 + 1161.66 X_3 + 3067.47 X_1 X_2 - 1077.94 X_1 X_3 + 222.78 X_2 X_3 - 2252.11 X_1 X_2 X_3$

Several studies have reported that increased oil levels can increase the globule size. This can be due to the coalescence of oil droplets and the added concentrations of surfactants or cosurfactants. Conversely, increasing the proportion of Lauroglycol-90 can reduce the globule size. RSM has been applied to analyze the effects of these selected factors. Contour plots and three-dimensional graphs for Response I are shown in Figure 4. The mixture's three components are depicted in the corners of the triangle, and the center portion illustrates the mixture.

(A)  

(B)  

(C)  

Figure 4. Contour and three-dimensional response surface graphs for (A) globule size, (B) Jss, and (C) inhibition zone.
3.4. Validation of Experimental Design

In the end, the experimental design was further validated to confirm its accuracy. The optimized formulation was prepared with the given conditions and evaluated for the globule size, Jss, and inhibition zone. The relative error was calculated by comparing the predicted and practical values, as shown in Table 8. The relative error was within the acceptable range (±5%), thus confirming the design’s preciseness. Generally, emulsions are thermodynamically stable isotropic systems in which two immiscible liquids are mixed to form a single phase utilizing an emulsifying agent, that is, a surfactant and cosurfactant. The droplet size of the nanoemulsion is typically in the range 20 to 300 nm for an optimized penetration with topical application. The results of the optimized formula showed a globule size of 245 nm which was in agreement with previously published data which indicated that, the globular size for any transdermal and topically applied vesicular drug delivery system is preferred to be less than 300 nm in order to penetrate easily through skin layers [42,43].

Table 8. Predicted versus experimental values for selected responses.

| Number | Parameter                | Predicted Values | Experimental Values | Relative Error (%) |
|--------|--------------------------|------------------|---------------------|--------------------|
| 1.     | Globule size (nm)        | 249              | 245                 | 1.6                |
| 2.     | Jss (μg/cm²/h)           | 222.05           | 228                 | -2.4               |
| 3.     | Inhibition zone (mm)     | 15               | 14.5                | 0.4                |

3.5. In Vitro Permeation/Release Study

The percentage of permeability through the cellulose membrane for the QRS and ITT was found to be 33.35 ± 2.17% and 59.43 ± 4.23% after 12 h (Figure 6). The Jss values further supported this finding. ITT had more Jss values, resulting in a higher level of permeation.

3.6. Ex Vivo Permeation Study

Ex vivo studies were conducted using a simple, low-head dissolution apparatus to establish the effect of the ITT-QRS formulations. The permeation was studied using rat full-thickness skin, and the results are summarized in Figure 6. An increased percentage of ITT permeation (52.11 ± 2.85%) was observed for the optimized nanoemulsion formulation. This can be credited to the synergistic action of Lauroglycol-90 and propylene glycol in
fluidizing the cell membranes and inhibiting the P-glycoprotein efflux. Another factor is the high level of permeation of nanoemulsion drug delivery systems. Nanoemulsions have proven to have relevance in clinical applications owing to their increased drug loading, enhanced drug solubility and bioavailability, reduced patient variability, controlled drug release, and protection from enzymatic degradation. A nanoemulsion can act like a drug reservoir in which the loaded drug is released into the outer phase and then into the skin.

![Figure 6](image-url)

**Figure 6.** In Vitro [In-v] and ex vivo [Ex-v] permeation and Jss results of the optimized formulation loaded with ITT-QRS SNEDDS. Data presented as the mean ± standard deviation. ($n = 3$). The level of significance was considered at $p < 0.05$.

### 3.7. In Vivo Studies

Despite several notable advancements, hepatic safety and hepatic cell regeneration products are inadequate for treating several liver disorders. Numerous herbal extract formulations were also used in this approach [44,45]. QRS is a natural flavonoid with exceptional antioxidant properties [46–49]. A significant alteration in hepato-specific liquid peroxidation and oxidative stress was observed with ITT. A similar result was observed in a few previous studies [50,51]. Table 9 shows the elevation of ALT and AST levels observed with formulations containing ITT alone.

#### Table 9. The effect of various formulation ingredients on hepato protective activity in comparison with the marketed formulation.

| Groups                                | AST Mean ± SD | ALT Mean ± SD | MDA Mean ± SD | GSH Mean ± SD |
|---------------------------------------|---------------|---------------|---------------|--------------|
| G1 [Control normal saline]            | 19.8 ± 1.89   | 21.85 ± 1.47  | 0.682 ± 0.029 | 636.47 ± 16.56 |
| G2 [Distilled water + ITT (Oral)]     | 38.5 ± 3.26   | 46.57 ± 4.54  | 1.278 ± 0.030 | 383.71 ± 13.8 |
| G3 [Distilled water + ITT (Topical)]  | 31.5 ± 3.50   | 38.225 ± 3.76 | 0.984 ± 0.021 | 445.09 ± 17.48 |
| G4 [Optimum ITT-QRS SNEDDS]           | 20.75 ± 2.61  | 22.035 ± 2.11 | 0.674 ± 0.033 | 660.30 ± 22.08 |
| G5 [Optimum ITT SNEDDS without QRS]   | 29.17 ± 2.62  | 36.895 ± 2.76 | 1024 ± 0.021  | 413.63 ± 25.76 |
| G6 [Optimum ITT SNEDDS without ITT]   | 19.16 ± 2.09  | 22.735 ± 1.58 | 0.696 ± 0.019 | 697.26 ± 22.08 |
| G7 [Marketed ITT cream]               | 34.41 ± 3.46  | 38.26 ± 2.07  | 0.956 ± 0.025 | 495.89 ± 19.32 |

Consistent with these results, a significant rise in the MDA levels and lipid peroxidation and a reduction in the antioxidant enzymes were supported by a significant decrease in the GSH-Px level.

Pretreatment with a formulation containing ITT plus quercetin for 14 days significantly increased the antioxidant characteristics and reduced the amount of lipid peroxidation, and this reduced the overall oxidative stress. All changes obtained with the QRS formulation (Group 4) were more beneficial in ameliorating hepatotoxicity compared with the formulation without QRS (Group 5). Additionally, Group 4 differed significantly from the marketed product (Group 7). No significant differences ($p > 0.05$) emerged in Group 5,
which was treated with the formula that lacked QRS and the commercially available ITT formulation, and Group 3, which was treated with topical ITT in an aqueous dispersion, for all tests.

4. Conclusions

In the present study, a topical nanoemulsion of ITT was successfully optimized in conjunction with QRS to enhance the permeability and to study the relevance of hepatoprotective agents from the formulation. ITT exhibited maximum solubility in the Lauroglycol-90 surfactant and propylene glycol cosurfactant, and this further optimized using the quality by design desirability approach (mixture design). A lower concentration of ITT favored small vesicle formation. The optimum formulation consisted of 0.25 g of rosehip oil, 0.45 g of a surfactant (Lauroglycol-90), and 0.3 g of a cosurfactant (propylene glycol). The range of relative error was acceptable (<5%), confirming the preciseness of the design. In vitro and ex vivo permeation studies confirmed the enhanced percentage of permeation of ITT and QRS, and in vivo studies further supported these results. The QRS had commensurate hepatoprotective activity in the prepared formulation and was found to be safe in comparison with formulations containing individual drugs and commercially marketed products. However, further clinical investigations are required to explore the commercial viability of the product.

Author Contributions: Conceptualization and methodology, K.M.H. and K.S.A.N.; software and validation, N.A.A.; formal analysis, K.M.H.; investigation, resources, and data curation, K.S.A.N.; writing—original draft preparation, K.S.A.N.; writing—review and editing, N.A.A.; visualization, N.A.A.; supervision and project administration, K.M.H. All authors have read and agreed to the published version of the manuscript.

Funding: This Project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under grant no. FP-138-42.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Animal Ethics Committee of the Beni-Suef Clinical Laboratory (Approval No. 22-09-20, at September 2020).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: This Project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under grant no. FP-138-42. The authors, therefore, acknowledge DSR for the technical and financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kanlayavattanakul, M.; Lourith, N. Therapeutic agents and herbs in topical application for acne treat-ment. Int. J. Cosmet. Sci. 2011, 33, 289–297. [CrossRef] [PubMed]
2. Agrawal, D.A.; Khunger, N. A morphological study of acne scarring and its relationship between se-verity and treatment of active acne. J. Cutan. Aesthet. Surg. 2020, 13, 210–216. [PubMed]
3. Fourniére, M.; Latire, T.; Souak, D.; Feuilloley, M.; Bedoux, G. Staphylococcus epidermidis and Cutibacterium acnes: Two Major Sentinels of Skin Microbiota and the Influence of Cosmetics. Microorganisms 2020, 8, 1752. [CrossRef] [PubMed]
4. Esmael, A.; Hassan, M.G.; Amer, M.M.; Abdelrahman, S.; Hamed, A.M.; Abd-Raboh, H.A.; Han, H. Antimicrobial activity of certain natural-based plant oils against the antibiotic-resistant acne bacteria. Saudi J. Biol. Sci. 2020, 27, 448–455. [CrossRef] [PubMed]
5. Nasri, H.; Bahmani, M.; Shahinfard, N.; Nafchi, A.M.; Saberianpour, S.; Rafieian-Kopaei, M. Medicinal Plants for the Treatment of Acne Vulgaris: A Review of Recent Evidences. Jundishapur J. Microbiol. 2015, 8, e25580. [CrossRef] [PubMed]
6. Totté, J.E.E.; Van Der Feltz, W.T.; Hennekam, M.; van Belkum, A.; Van Zuuren, E.J.; Pasmans, S.G.M.A. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: A systematic review and me-ta-analysis. Br. J. Dermatol. 2016, 175, 687–695. [CrossRef]
7. Oge’, L.K.; Broussard, A.; Marshall, M.D. Acne Vulgaris: Diagnosis and Treatment. Am. Fam. Phys. 2019, 100, 475–484.
8. Gollnick, H.; Zouboulis, C.C. Not All Acne Is Acne Vulgaris.Dtisic. Aerzteblatt Online 2014, 111, 301–312. [CrossRef]
9. Espinosa, N.I.; Cohen, P.R. Acne Vulgaris: A Patient and Physician’s Experience. Dermatol. Ther. 2020, 10, 1–14. [CrossRef]
10. Zaenglein, A.L.; Pathy, A.L.; Schlosser, B.J.; Alikhan, A.; Baldwin, H.E.; Berson, D.S.; Bowe, W.P.; Graber, E.M.; Harper, J.C.; Kang, S.; et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2016, 74, 945–973.e33. [CrossRef]

11. Tan, A.U.; Schlosser, B.J.; Paller, A.S. A review of diagnosis and treatment of acne in adult female patients. Int. J. Womens Dermatol. 2018, 4, 56–71. [CrossRef] [PubMed]

12. Leyden, J.J.; James, W.D. Staphylococcus aureus Infection as a Complication of Isotretinoin Therapy. Arch. Dermatol. 1987, 123, 5–7. [CrossRef]

13. Ahmadv, H.; Javanbakht, A.M.A.; Pour, H.M. M Effects of oral isotretinoin on serum lipids and gamma glutamyl transpeptidase activity in acne vulgaris patients. Afr. J. Pharm. Pharmacol. 2011, 5, 1338–1341. [CrossRef]

14. Bocquet, L.; Sahpaz, S.; Bonneau, N.; Beaufay, C.; Mahieux, S.; Samaillie, J.; Roumy, V.; Jacquin, J.; Bordage, S.; Hennebelle, T.; et al. Phenolic compounds from humulus lupulus as natural antimicrobial products: New weapons in the fight against methicillin resistant Staphylococcus aureus, leishmania mexicana and trypa-nosoma brucei strains. Molecules 2019, 24, 1024. [CrossRef] [PubMed]

15. Wang, R.; Zhang, H.; Wang, Y.; Song, F.; Yuan, Y. Inhibitory effects of quercetin on the progression of liver fibrosis through the regulation of NF-κB/IkBα, p38 MAPK, and Bcl-2/Bax signaling. Int. Immunopharmacol. 2017, 47, 126–133. [CrossRef] [PubMed]

16. Oršolić, N.; Knezevic, A.H.; Šver, L.; Terzić, S.; Basic, I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J. Ethnopharmacol. 2004, 94, 307–315. [CrossRef] [PubMed]

17. Chirumbolo, S. The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function. Inflamm. Allergy Drug Targets 2010, 9, 263–285. [CrossRef]

18. Li, Y.; Yao, J.; Han, C.; Yang, J.; Chaudhry, M.T.; Wang, S.; Liu, H.; Yin, Y. Quercetin, Inflammation and Immunity. Nutrients 2016, 8, 167. [CrossRef]

19. Massi, A.; Bortolini, O.; Ragno, D.; Bernardi, T.; Sacchetti, G.; Tacchini, M.; De Risi, C. Research Progress in the Modification of Quercetin Leading to Anticancer Agents. Molecules 2017, 22, 1270. [CrossRef]

20. Aguirre, L.; Arias, N.; Teresa Macarulla, M.; Gracia, A.; Portillo, M.P. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J. 2011, 4, 189–198.

21. Lu, B.; Huang, Y.; Chen, Z.; Ye, J.; Xu, H.; Chen, W.; Long, X. Niosomal nanocarriers for enhanced skin delivery of quercetin with functions of an-ti-tyrosinase and antioxidant. Molecules 2019, 24, 2322. [CrossRef] [PubMed]

22. Ganesan, P.; Choi, D.K. Current application of phyto compound-based nanocosmeceuticals for beauty and skin therapy. Int. J. Nanomed. 2016, 11, 1987–2007. [CrossRef] [PubMed]

23. Kazi, M.; Al-Swairi, M.; Ahmad, A.; Raish, M.; Alanazi, F.K.; Badran, M.M.; Khan, A.A.; Alanazi, A.M.; Hussain, M.D. Evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for poorly wa-ter-soluble talinolol: Preparation, in vitro and in vivo assessment. Int. J. Nanomed. 2019, 14, 5887–5907. [CrossRef] [PubMed]

24. Izham, M.N.M.; Hussin, Y.; Aziz, M.N.M.; Yeap, S.K.; Rahman, H.S.; Masarudin, M.J.; Mohamad, N.E.; Rasedee, A.; Alitheen, N.B. Preparation and Characterization of Self Nano-Emulsifying Drug Delivery System Loaded with Citraland Its Antiproliferative Effect on Colorectal Cells In Vitro. Nanomaterials 2019, 9, 1028. [CrossRef]

25. Kang, B.K.; Lee, J.S.; Choi, K.; Jeong, S.Y.; Yuk, S.H.; Khang, G.; Lee, H.B.; Cho, S.H. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bio-availability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 2004, 274, 65–73. [CrossRef]

26. Nasr, A.; Gandouh, A.; Ghorab, M. Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: Formulation, pharmacokinetic and bioavailability eval-uation. Pharmaceuticals 2016, 8, 20. [CrossRef]

27. Dou, Y.X.; Zhou, J.T.; Wang, T.T.; Huang, Y.F.; Chen, V.P.; Xie, Y.L.; Lin, Z.X.; Gao, J.S.; Su, Z.R.; Zeng, H.F. Self-nanoemulsifying drug delivery system of brucine D: A new approach for an-ti-ulcerative colitis. Int. J. Nanomed. 2018, 13, 5887–5907. [CrossRef]

28. Date, A.A.; Desai, N.; Dixit, R.; Nagarsenker, M. Self-nanoemulsifying drug delivery systems: Formula-tion insights, applications and advances. Nanomedicine 2010, 5, 1595–1616. [CrossRef]

29. Bernardi, D.S.; Pereira, T.A.; Maciel, N.R.; Bortoloto, J.; Viera, G.S.; Oliveire, G.C.; Filho, P.A.D.R. Formation and stability of oil-in-water nanoemulsions containing rice bran oil: In vitro and in vivo assessments. J. Nanobiotechnol. 2011, 9, 44. [CrossRef]

30. Jang, M.H.; Piao, X.L.; Kim, J.M.; Kwon, S.W.; Park, J.H. Inhibition of cholinesterase and amyloid-β&agr; aggregation by resveratrol oligomers from Vitis amurensis. Phyther. Res. 2008, 22, 544–559.

31. De Santana, F.B.; Gontijo, L.C.; Mitsutake, H.; Mazivila, S.J.; De Souza, L.M.; Neto, W.B. Non-destructive fraud detection in rosehip oil by MIR spectroscopy and chemometrics. Food Chem. 2016, 209, 228–233. [CrossRef] [PubMed]

32. Alvarez-Figueroa, M.; Blanco-Méndez, J. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int. J. Pharm. 2001, 215, 57–65. [CrossRef]

33. Djekic, L.; Primorac, M. The influence of cosurfactants and oils on the formation of pharmaceutical micro-emulsions based on PEG-8 caprylic/capric glycerides. Int. J. Pharm. 2008, 352, 231–239. [CrossRef] [PubMed]

34. Hosny, K.M.; Ahmad, O.A.A.; Fahmy, M.A.; Alkhalihi, H.M. Nanovesicular systems loaded with a recently approved second generation type-5 phosphodiesterase inhibitor (avanafil): I. Plackett-Burman screening and characterization. J. Drug Deliv. Sci. Technol. 2018, 43, 154–159. [CrossRef]

35. Souto, E.B.; Baldim, I.; Oliveira, W.P.; Rao, R.; Yadav, N.; Gama, F.M.; Mahant, S. SLN and NLC for topical, dermal, and transdermal drug delivery. Expert Opin. Drug Deliv. 2020, 17, 357–377. [CrossRef]
36. Rohaninasab, M.; Behrangi, E.; Nahad, Z.M.; Rasi, A. Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne. *Adv. Biomed. Res.* **2014**, *3*, 103. [CrossRef]

37. Alharbi, W.S.; Hosny, K.M. Development and optimization of ocular in situ gels loaded with ciprofloxacin cubic liquid crystalline nanoparticles. *J. Drug Deliv. Sci. Technol.* **2020**, *57*, 101710. [CrossRef]

38. Hosny, K.M. Nanosized Cubosomal Thermogelling Dispersion Loaded with Saquinavir Mesylate to Improve Its Bioavailability: Preparation, Optimization, in vitro, and in vivo Evaluation. *Int. J. Nanomed.* **2020**, *15*, 5113–5129. [CrossRef]

39. Shao, M.; Hussain, Z.; Thu, H.E.; Khan, S.; Katas, H.; Ahmed, T.A.; Tripathy, M.; Leng, J.; Qin, H.L.; Bukhari, S.N.A. Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease. *Coll. Surf. B Biointerfaces* **2016**, *147*, 475–491. [CrossRef] [PubMed]

40. Hosny, K.M.; Rizg, W.Y. Quality by design approach to optimize the formulation variables influencing the characteristics of biodegradable intramuscular in-situ gel loaded with alendronate sodium for osteoporosis. *PLoS ONE* **2018**, *13*, e0197540. [CrossRef] [PubMed]

41. Lai, C.; Li, C.; Liu, M.; Qiu, Q.; Luo, X.; Liu, X.; Hu, L.; Deng, Y.; Song, Y. Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes. *Asian J. Pharm. Sci.* **2019**, *14*, 455–464. [CrossRef]

42. Kassem, A.A.; Abd El-Alim, S.H. Vesicular Nanocarriers: A Potential Platform for Dermal and Transdermal Drug Delivery. *Nanopharm. Princ. Appl.* **2020**, *2*, 155–209.

43. Hanifah, M.; Jufri, M. Formulation and Stability Testing of Nanoemulsion Lotion Containing Centella asiatica Extract. *J. Young Pharm.* **2018**, *10*, 404–408. [CrossRef]

44. Gaba, B.; Fazil, M.; Khan, S.; Ali, A.; Baboota, S.; Ali, J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. *Bull. Fac. Pharm. Cairo Univ.* **2015**, *53*, 147–159. [CrossRef]

45. Pashirova, T.N.; Lukashenko, S.S.; Zakharov, S.V.; Voloshina, A.D.; Zhiltsova, E.P.; Zobov, V.V.; Souto, E.B.; Zakharova, L.Y. Self-assembling systems based on quaternized derivatives of 1,4-diazabicyclo[2.2.2]octane in nutrient broth as antimicrobial agents and carriers for hydrophobic drugs. *Coll. Surf. B Biointerfaces* **2015**, *127*, 266–273. [CrossRef]

46. Sharma, V.; Chaudhary, U. An overview on indigenous knowledge of Achyranthes aspera. *J. Crit. Rev.* **2015**, *2*, 7–19.

47. Gupta, C.; Vikram, A.; Tripathi, D.N.; RamaRao, P.; Jena, G. Antioxidant and antimutagenic effect of quercetin against DEN induced hepatotoxicity in rat. *Phytother. Res.* **2009**, *24*, 119–128. [CrossRef]

48. Rubio-Ruiz, M.E.; Guarnier-Lans, V.; Cano-Martinez, A.; Diaz-Diaz, E.; Manzano-Pech, L.; Gamas-Magaña, A.; Castrejon-Tellez, V.; Tapia-Cortina, C.; Perez-Torres, I. Resveratrol and quercetin administration improves anti-tioxidant defenses and reduces fatty liver in metabolic syndrome rats. *Molecules* **2019**, *24*, 1297. [CrossRef]

49. Ilari, S.; Giancotti, L.A.; Lauro, F.; Gliozzi, M.; Malafoglia, V.; Palma, E.; Tafani, M.; Russo, M.A.; Tomino, C.; Fini, M.; et al. Natural Antioxidant Control of Neuropathic Pain—Exploring the Role of Mitochondrial SIRT3 Pathway. *Antioxidants* **2020**, *9*, 1103. [CrossRef]

50. Lee, Y.H.; Scharnitz, T.P.; Muscat, J.; Chen, A.; Gupta-Elera, G.; Kirby, J.S. Laboratory monitoring during isotretinoin therapy for acne: A systematic review and meta-analysis. *JAMA Dermatol.* **2016**, *152*, 35–44. [CrossRef]

51. Goforoushan, F.; Azimi, H.; Goldust, M. Efficacy of Vitamin E to Prevent Dermal Complications of Isotretinoin. *Pak. J. Biol. Sci.* **2013**, *16*, 548–550. [CrossRef] [PubMed]